Sign in with Google
bullish
JOINN Laboratories - Q3 Performance in Line with Expectations; Promising Globalization After HK IPO
284 Views15 Nov 2020 02:43
The article analyzed JOINN Lab's Q3 performance in both business and financial aspects, and also made forecast and rating for the Company.
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 5-minute read)
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- TIP Customized Taiwan Select High Div Index Rebal Preview: Methodology Change Leads to US$9bn Trade
- NWD (17 HK): Markets Pricing In A Bust
- HSI, HSCEI, HSTECH, HSIII Index Rebalance: US$8.1bn of Flows Post Capping (June 2025)
- [Japan Activism] Pasona Group (2168 JP) - Three New Things Of Mixed Importance
- From Rust to Riches: The Next Copper Boom
Top Unpaywalled Insights
More »- VEON US: Pakistan Towers Sale Frees Capital for Digital Growth in Core Market Ahead of Ukraine IPO
- Advanced Look: Navigating the New Macro Landscape Through Quantitative Alpha Generation Strategies
- [IO Technicals 2025/22] Bearish Momentum Strengthens
- Texas Power Play: Grid Sovereignty, Bitcoin, and the Future of AI
- Overview #27 – The Big Beautiful Tragi-Comedy Continues
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- China Healthcare Weekly (Feb.19) - VBP on Biosimilar Drugs, Poor Performance of Healthcare Sector22 Feb 2021
- Innovent Biologics (1801 HK) - Have the Genes to Become a Big Pharma18 Feb 2021
- Pre-IPO Joinn Laboratories - The Future Performance Is Worth Looking Forward To16 Feb 2021
- JOINN Laboratories - Q3 Performance in Line with Expectations; Promising Globalization After HK IPO15 Nov 2020
- JD Health (京东健康) Pre-IPO - Assumptions and Valuations13 Nov 2020
- Insights on China Healthcare Policy: New Intensive Procurement Policy for High-Value Medical Devices12 Nov 2020
- Insights On China Healthcare Policy - 4+7: New Volume-Based Purchasing Policy22 Oct 2020
x